Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adefovir dipivoxil.

María Buti1, Rafael Esteban

  • 1Liver Unit, Hospital General Universitari Vall d' Hebron, Barcelona, Spain. mbuti@hg.vhebron.es

Drugs of Today (Barcelona, Spain : 1998)
|April 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of a mobile application for the management of hepatitis D based on patient experience: an observational study in a hepatology cohort.

Gastroenterologia y hepatologia·2026
Same author

No impact of low-dose nivolumab addition to JNJ-73763989 on HBsAg declines in chronic hepatitis B: the OCTOPUS-1 study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence-Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

The New England journal of medicine·2026
Same author

Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in Catalonia.

Scientific reports·2026
Same author

Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort.

JHEP reports : innovation in hepatology·2026
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Adefovir dipivoxil is a new oral antiviral for chronic hepatitis B, effective against wild-type and lamivudine-resistant strains. Its excellent safety profile and lack of detected resistance make it a valuable treatment option.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B virus (HBV) infection remains a significant global health concern.
  • Current antiviral therapies face challenges with drug resistance and limited efficacy.
  • Nucleotide analogues represent a promising class of antiviral agents for HBV treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of adefovir dipivoxil for chronic hepatitis B treatment.
  • To assess adefovir dipivoxil's activity against wild-type and lamivudine-resistant HBV strains.
  • To establish adefovir dipivoxil as a new therapeutic option for chronic hepatitis B.

Main Methods:

  • In vitro and in vivo studies were conducted to assess adefovir's antiviral activity.
  • Clinical trials evaluated the efficacy and safety of adefovir dipivoxil at a recommended dose of 10 mg daily.

Related Experiment Videos

  • Resistance patterns of HBV to adefovir dipivoxil were monitored.

    • Main Results:

    • Adefovir dipivoxil demonstrated potent antiviral effects against herpesviruses, retroviruses, and hepadnaviruses, including HBV.
    • The drug effectively inhibited both wild-type and lamivudine-resistant HBV strains.
    • Excellent safety profile observed at the recommended dose; higher doses may cause renal tubular damage.
    • No evidence of HBV resistance to adefovir dipivoxil has been detected.

    Conclusions:

    • Adefovir dipivoxil is a significant advancement in chronic hepatitis B therapy.
    • It offers a valuable treatment option for both HBeAg-positive and anti-HBe-positive chronic hepatitis B.
    • Adefovir dipivoxil serves as effective rescue therapy for lamivudine-resistant HBV strains, with potential for longer treatment durations due to lack of resistance.